• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Ventyx Biosciences Inc.

    2/28/25 8:15:59 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTYX alert in real time by email
    S-8 1 d936519ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 28, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    VENTYX BIOSCIENCES, INC.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   83-2996852

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    12790 El Camino Real, Suite 200

    San Diego, CA 92130

    (Address of principal executive offices, including zip code)

    2021 Equity Incentive Plan

    2021 Employee Stock Purchase Plan

    (Full title of the plan)

    Raju Mohan, PhD

    Chief Executive Officer

    Ventyx Biosciences, Inc.

    662 Encinitas Blvd, Suite 250

    Encinitas, CA 92024

    (Name and address of agent for service)

    (760) 593-4832

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Martin J. Waters

    Phillip McGill

    Wilson Sonsini Goodrich & Rosati, P.C.

    12235 El Camino Real

    San Diego, California 92130

    (858) 350-2300

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

     

    ☐

      

    Accelerated filer

     

    ☐

    Non-accelerated filer

     

    ☒

      

    Smaller reporting company

     

    ☒

        

    Emerging growth company

     

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    Ventyx Biosciences, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register (i) 3,556,502 additional shares of common stock of the Registrant, par value $0.0001 per share (“Common Stock”) under the Registrant’s 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to the provision of the 2021 Plan providing for such automatic increase in the number of shares reserved for issuance, and (ii) 711,300 additional shares of Common Stock under the Registrant’s 2021 Employee Stock Purchase Plan (the “2021 ESPP”), pursuant to the provision of the 2021 ESPP providing for such automatic increase in the number of shares reserved for issuance.

    Accordingly, contents of (i) the previous Registration Statement on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on January 2, 2024 (File No. 333-276347), (ii) the previous Registration Statement on Form S-8 filed by the Registrant with the Commission on January 5, 2023 (File No. 333-269130), and (iii) the previous Registration Statement on Form S-8 filed by the Registrant with the Commission on October 21, 2021 (File No. 333-260416) (together, the “Previous Forms S-8”), including the information incorporated by reference therein and the periodic reports filed after the Previous Forms S-8 to maintain current information about the Registrant, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8 (the “Registration Statement”).

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.


    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

    (1) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025 (the “Annual Report”) pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);

    (2) All other reports filed by the Registrant with the Commission pursuant to Sections 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report (other than the portions of these documents not deemed to be filed); and

    (3) The description of the Registrant’s Common Stock contained in Exhibit 4.3 to the Company’s Annual Report on Form 10-K filed with the Commission on March 24, 2022, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 8. Exhibits.

     

              Incorporated by Reference

    Exhibit

    Number

      

    Description

       Form    File No.    Exhibit    Filing Date
      4.1    Specimen common stock certificate of the Registrant    S-1/A    333-259891    4.2    October 15, 2021
      5.1*    Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation            
     23.1*    Consent of Independent Registered Public Accounting Firm            
     23.2*    Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)            
     99.1    2021 Equity Incentive Plan, as amended, and forms of agreement thereunder    10-K    001-40928    10.3    March 23, 2023
     99.2    2021 Employee Stock Purchase Plan    S-1/A    333-259891    10.4    October 15, 2021
    107.1*    Filing Fee Table            

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on February 28, 2025.

     

    VENTYX BIOSCIENCES, INC.
    By:   /s/ Raju Mohan
      Raju Mohan, Ph.D.
      President and Chief Executive Officer

    Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature

      

    Title

     

    Date

    /s/ Raju Mohan

    Raju Mohan, Ph.D.

      

    Chief Executive Officer and Director

    (Principal Executive Officer)

      February 28, 2025

    /s/ Roy Gonzales

    Roy Gonzales

      

    Senior Vice President, Finance

    (Principal Financial Officer and Principal Accounting Officer)

      February 28, 2025

    /s/ Sheila Gujrathi

    Sheila Gujrathi, M.D.

       Executive Chairperson   February 28, 2025

    /s/ Onaiza Cadoret-Manier

    Onaiza Cadoret-Manier

       Director   February 28, 2025

    /s/ Allison J. Hulme

    Allison J. Hulme, Ph.D.

       Director   February 28, 2025

    /s/ Somasundaram Subramaniam

    Somasundaram Subramaniam, M.B.A.

       Director   February 28, 2025

    /s/ William White

    William White, J.D., M.P.P.

       Director   February 28, 2025
    Get the next $VTYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTYX

    DatePrice TargetRatingAnalyst
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    3/12/2024$12.00Perform → Outperform
    Oppenheimer
    3/12/2024$7.00 → $16.00Equal Weight → Overweight
    Wells Fargo
    11/7/2023$46.00 → $6.00Overweight → Equal-Weight
    Morgan Stanley
    11/7/2023Outperform → Perform
    Oppenheimer
    11/7/2023Buy → Neutral
    H.C. Wainwright
    11/7/2023$6.00Buy → Hold
    Stifel
    11/7/2023$77.00 → $8.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $VTYX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

    Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in inflammatory-mediated diseases INDIANAPOLIS, Jan. 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (NASDAQ:VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, today announced entry into a definitive agreement for Lilly to acquire Ventyx. Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation acr

    1/7/26 4:17:00 PM ET
    $LLY
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Provides Clinical and Corporate Updates

    Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development planInterim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx's R&D Day planned for Q1 2026 SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerativ

    12/2/25 7:02:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

    SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York. Piper Sandler 37th Annual Healthcare Conference details:Fireside ChatDate: Wednesday, December 3, 2025Time: 4:00 – 4:25 PM ET A live webcast of the event will be available In the Investors and News section of the Ventyx website at https://ventyxbio.com/. A w

    12/1/25 7:02:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Nuss John sold $97,840 worth of shares (12,675 units at $7.72) and converted options into 34,930 shares, increasing direct ownership by 5% to 489,481 units (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    12/19/25 4:15:07 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO AND PRESIDENT Mohan Raju converted options into 116,668 shares and sold $365,461 worth of shares (47,345 units at $7.72), increasing direct ownership by 3% to 2,372,863 units (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    12/19/25 4:15:09 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Forman Mark S was granted 3,000 shares, increasing direct ownership by 100% to 6,000 units (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    11/19/25 4:30:10 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Ventyx Biosciences Inc.

    SCHEDULE 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    2/6/26 4:13:53 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Ventyx Biosciences Inc.

    SCHEDULE 13G - Ventyx Biosciences, Inc. (0001851194) (Subject)

    2/5/26 4:53:27 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFM14A filed by Ventyx Biosciences Inc.

    DEFM14A - Ventyx Biosciences, Inc. (0001851194) (Filer)

    2/2/26 4:05:24 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gujrathi Sheila bought $300,573 worth of shares (130,000 units at $2.31) (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    12/26/24 8:05:18 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO AND PRESIDENT Mohan Raju bought $959,889 worth of shares (500,000 units at $1.92), increasing direct ownership by 30% to 2,175,028 units (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    11/25/24 9:07:34 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ventyx Biosciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Ventyx Biosciences from Neutral to Buy and set a new price target of $18.00

    11/5/25 7:25:28 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Ventyx Biosciences from Perform to Outperform and set a new price target of $12.00

    3/12/24 7:35:44 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Ventyx Biosciences from Equal Weight to Overweight and set a new price target of $16.00 from $7.00 previously

    3/12/24 7:35:12 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Leadership Updates

    Live Leadership Updates

    View All

    Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

    Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized scientists and clinicians to its Scientific Advisory Board (SAB): Mo Lamkanfi, PhD, Luke O'Neill, PhD, Ted Dawson, MD, PhD, Martin Pomper, MD, PhD, Antonio Abbate, MD, PhD, Paul Cremer, MD

    4/1/25 7:00:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

    A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024 Mark Forman, MD, PhD will join Ventyx as Chief Medical Officer effective August 12, 2024 Cash, cash equivalents and marketable securities of $279.7 million as of June 30, 2024 are expected to fund planned operations into at least the second half of 2026 SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapie

    8/8/24 4:01:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

    SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer. "I am excited to welcome Matt to the Ventyx leadership team," said Raju Mohan, Chief Executive Officer. "He brings a wealth of expertise to Ventyx from his multiple decades in the biopharma industry. In his role as COO, Matt will play an important role in driving corporate operations, business development and strategy." "I am excited to

    5/16/24 8:00:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 3:06:49 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 8:57:39 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Financials

    Live finance-specific insights

    View All

    Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

    VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first weekVTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of ≤1.65ng/L1Statistically significant reductions in Lp(a) and liver inflammationNo effect on weight either as a monotherapy or as add-on to semaglutide VTX3232 was safe and well tolerated both as a monotherapy and add-on to semaglutide in this studyVentyx to hold conference call and webcast 4:30pm ET on Wednesday, October 22nd SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences,

    10/22/25 4:02:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

    Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson's disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as of March 31, 2024 are expected to fund planned operations into at least the second half of 2026 Ventyx to host conference call and webcast today at 4:30PM ET SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medi

    5/9/24 4:01:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

    SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on May 9, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. To participate in the conference call, please dial (800) 343-4849 (U.S.) or (203) 518-9848 (international)

    5/2/24 4:05:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care